Study Evaluating Changes In Mammographic Breast Density
Completed · Has a placebo group
Conditions studied: Osteoporosis
In brief
The objective of the study is to evaluate quantitative changes in mammographic breast density from baseline to 24 months in postmenopausal women receiving daily doses of either BZA 20 mg/CE 0.45 mg, BZA 20 mg/CE 0.625 mg, Raloxifene or placebo. The primary endpoint in this study is the change in mammographic breast density between baseline and month 24 for each group.
Key facts
- Study ID
- NCT00774267
- Run by
- Pfizer
- People needed
- 507
- Starts
- 2009-01-01
- Expected to finish
- 2010-04-01
- Last updated by the study team
- 2014-04-08
Who can join
Age: 40 and older, up to 75. Sex: female. Healthy volunteers: not accepted.
You may qualify if…
- Subjects who have completed all scheduled evaluations in protocol 3115A1-303-WW.
- Completed 24 months of treatment in protocol 3115A1-303.
- Had a mammogram at the baseline visit and at the month 24 visit in protocol 3115A1-303, and both are original films that are technically acceptable for reading.
- Was at least 80% compliant with test article administration during protocol 3115A1-303.
You may not qualify if…
- Had a mammogram at either baseline or month 24 during the 3115A1-303 study that was technically unsatisfactory.
- One or both mammograms were digitized when they were obtained during the 3115A1-303 study.
- Had more than one mammogram at either the baseline or month 24 visit of study 3115A1-303.
Where it is running
- Pfizer Investigational Site — Fort Myers, Florida, United States
- Pfizer Investigational Site — Gainesville, Florida, United States
- Pfizer Investigational Site — New Port Richey, Florida, United States
- Pfizer Investigational Site — West Palm Beach, Florida, United States
- Pfizer Investigational Site — Decatur, Georgia, United States
- Pfizer Investigational Site — Chicago, Illinois, United States
- Pfizer Investigational Site — Lexington, Kentucky, United States
- Pfizer Investigational Site — Lousiville, Kentucky, United States
- Pfizer Investigational Site — Southfield, Michigan, United States
- Pfizer Investigational Site — Chaska, Minnesota, United States
- Pfizer Investigational Site — Billings, Montana, United States
- Pfizer Investigational Site — Las Vegas, Nevada, United States
- Pfizer Investigational Site — New Brunswick, New Jersey, United States
- Pfizer Investigational Site — Rochester, New York, United States
- Pfizer Investigational Site — Raleigh, North Carolina, United States
- Pfizer Investigational Site — Cincinnati, Ohio, United States
- Pfizer Investigational Site — Wexford, Pennsylvania, United States
- Pfizer Investigational Site — Greenville, South Carolina, United States
- Pfizer Investigational Site — Dallas, Texas, United States
- Pfizer Investigational Site — San Antonio, Texas, United States
- Pfizer Investigational Site — Charlottesville, Virginia, United States
- Pfizer Investigational Site — Norfolk, Virginia, United States
- Pfizer Investigational Site — São Paulo, RS/Brazil, Brazil
- Pfizer Investigational Site — Nijmegen, Netherlands
- Pfizer Investigational Site — Bergen, Norway
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.